Bortezomib induces different apoptotic rates in B-CLL cells according to IgVH and BCL-6 mutations

Clinical and Translational Oncology

Volumn 8, Issue 11, 2006, Pages 805-811

  Jantus Lewintre, Eloisa ^a,b   Sarsotti, Elena ^a   Terol, María José ^a   Benet, Isabel ^a   Garciá Conde, Javier ^b,c  

^a HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^b CENTRO DE INVESTIGACIÓN PRÍNCIPE FELIPE   (Spain)

^c UNIVERSITY OF VALENCIA   (Spain)

Author keywords

BCL 6; Bortezomib; IgVH; NF Band CLL

Indexed keywords

3 (4 METHYLPHENYLSULFONYL) 2 PROPENENITRILE; BORTEZOMIB; CASPASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOGLOBULIN HEAVY CHAIN; PROTEIN BCL 6; 3-(4-METHYLPHENYLSULFONYL)-2-PROPENENITRILE; ANTINEOPLASTIC AGENT; BENZYLOXYCARBONYLVALYL ALANYL ASPARTYL FLUOROMETHYL KETONE; BENZYLOXYCARBONYLVALYL-ALANYL-ASPARTYL FLUOROMETHYL KETONE; BORONIC ACID DERIVATIVE; CD38 ANTIGEN; CYSTEINE PROTEINASE INHIBITOR; I KAPPA B; I KAPPA B KINASE; NITRILE; PEPTIDE CHLOROMETHYL KETONE; PROTEIN KINASE INHIBITOR; PROTEIN KINASE ZAP 70; PROTEIN TYROSINE KINASE; PYRAZINE DERIVATIVE; SULFONE; TUMOR PROTEIN;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; B CELL LEUKEMIA; CANCER STAGING; CELL ISOLATION; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVATION; FEMALE; GENE MUTATION; HUMAN; HUMAN CELL; IN VITRO STUDY; LEUKEMIA CELL; MALE; MUTATIONAL ANALYSIS; NUCLEOTIDE SEQUENCE; BIOSYNTHESIS; CELL CULTURE; COMPARATIVE STUDY; DOSE RESPONSE; DRUG ANTAGONISM; DRUG SCREENING; GENE REARRANGEMENT; GENETICS; IMMUNOGLOBULIN GENE; IMMUNOGLOBULIN VARIABLE REGION; METABOLISM; MIDDLE AGED; PATHOLOGY; PHOSPHORYLATION; PHYSIOLOGY; PROTEIN PROCESSING;

ADULT; AGED; AGED, 80 AND OVER; AMINO ACID CHLOROMETHYL KETONES; ANTIGENS, CD38; ANTINEOPLASTIC AGENTS; APOPTOSIS; BORONIC ACIDS; CASPASES; CYSTEINE PROTEINASE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; GENE REARRANGEMENT, B-LYMPHOCYTE, HEAVY CHAIN; GENES, IMMUNOGLOBULIN; HUMANS; I-KAPPA B KINASE; I-KAPPA B PROTEINS; IMMUNOGLOBULIN HEAVY CHAINS; IMMUNOGLOBULIN VARIABLE REGION; LEUKEMIA, B-CELL, CHRONIC; MALE; MIDDLE AGED; NEOPLASM PROTEINS; NF-KAPPA B; NITRILES; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS C-BCL-6; PYRAZINES; SULFONES; TUMOR CELLS, CULTURED; ZAP-70 PROTEIN-TYROSINE KINASE;

EID: 39049187930     PISSN: 1699048X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12094-006-0136-3     Document Type: Article

References (29)

1. Dighiero G. CLL Biology and Prognosis. Hematology. Am Soc Hematol Educ Program. 2005, p. 278-84.
2. Chiorazzi N, Rai KR, Ferrarini M. Chronic lymphocytic leukemia. N Engl J Med. 2005; 552:804-15.
3. Damle RN, Wasil T, Fais F, et al. IgV gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood. 1999;94:1840-7.
4. Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK. Unmutated IgV(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood. 1999;94:1848-54.
5. Sarsotti E, Marugan I, Benet I, et al. Bcl-6 mutation status provides clinically valuable information in early-stage B-cell chronic lymphocytic leukemia. Leukemia. 2004;18:743-6.
6. Furman RR, Asgary Z, Mascarenhas JO, Liou HC, Schattner EJ. Modulation of NF-kappa B activity and apoptosis in chronic lymphocytic leukemia B cells. J Immunol. 2000;164:2200-6.
7. Baldwin AS. Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB. J Clin Invest. 2001;107:241-6.
8. Ghosh S, May MJ, Kopp EB. NF-kappa B and Rel proteins: Evolutionarily conserved mediators of immune responses. Annu Rev Immunol. 1998;16:225-60.
9. Voorhees PM, Dees EC, O'Neil B, Orlowski RZ. The proteasome as a targel for cancer therapy. Clin Cancer Res. 2003;9:6516-25.
10. Almond JB, Snowden RT, Hunter A, Dinsdale D, Cain K, Cohen GM. Proteasome inhibitor-induced apoptosis of B-chronic lymphocytic leukaemia cells involves cytochrome c release and caspase activation, accompanied by formation of an approximately 700 kDa Apaf-1 containing apoptosome complex. Leukemia, 2001;15:1388-97.
11. Pham LV, Tamayo AT, Yoshimura LC, Lo P, Ford RJ. Inhibition of constitutive NF-kappa B activation in mantle cell lymphoma B cells leads to induction of cell cycle arrest and apoptosis. J Immunol. 2003;171:88-95.
12. Pierce JW, Schoenleber R, Jesmok G, et al. Novel inhibitors of cytokine-induced IkappaBalpha phosphorylation and endothelial cell adhesion molecule expression show anti-inflammatory effects in vivo. J Biol Chem. 1997;272:21096-103.
13. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988;16:1215.
14. Kuppers R, Zhao M, Hansmann ML, Rajewsky K. Tracing B cell development in human germinal centres by molecular analysis of single cells picked from histological sections. Embo J. 1993;12:4955-67.
15. Migliazza A, Martinotti S, Chen W, et al. Frequent somatic hypermutation of the 5' noncoding region of the BCL6 gene in B-cell lymphoma. Proc Natl Acad Sci U S A. 1995;92:12520-4.
16. Kelley TW, Alkan S, Srkalovic G, Hsi ED. Treatment of human chronic lymphocytic leukemia cells with the proteasome inhibitor bortezomib promotes apoptosis. Leuk Res. 2004;28:845-50.
17. Pérez-Galán P, Roue G, Villamor N, Montserrat E, Campo E, Colomer D. The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status. Blood. 2006;107:257-64.
18. Nencioni AHF, Dillon CP, Yokoo R, et al. Evidence for a protective role of Mcl-1 in proteasome inhibitor-induced apoptosis. Blood. 2005;105:3255-62.
19. Hideshima T, Chauhan D, Richardson P, et al. NF-kappa B as a therapeutic target in multiple myeloma. J Biol Chem. 2002; 277:16639-47.
20. Reed JC, Pellecchia M. Apoptosis-based therapies for hematologic malignancies. Blood. 2005;106:408-18.
21. Duechler M, Shehata M, Schwarzmeier ID, Hoelbl A, Hilgarth M, Hubmann R. Induction of apoptosis by proteasome inhibitors in B-CLL cells is associated with downregulation of CD23 and inactivation of Notch2. Leukemia. 2005;19:260-7.
22. Rodríguez A, Martínez N, Camacho FI, et al. Variability in the degree of expression of phosphorylated IkappaBalpha in chronic lymphocytic leukemia cases with nodal involvement. Clin Cancer Res. 2004; 10:6796-806.
23. Chandra J, Gilbreath J, Freireich EJ, et al. Protease activation is required for glucocorticoid-induced apoptosis in chronic lymphocytic leukemic lymphocytes. Blood. 1997;90:3673-81.
24. Kitada S, Andersen J, Akar S, et al. Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: Correlations with in vitro and in vivo chemoresponses. Blood. 1998;91:3379-89.
25. King D, Pringle JH, Hutchinson M, Cohen GM. Processing/activation of caspases, -3 and -7 and -8 but not caspase-2, in the induction of apoptosis in B-chronic lymphocytic leukemia cells. Leukemia. 1998; 12:1553-60.
26. Yamochi T, Kaneita Y, Akiyama T, Mori S, Moriyama M. Adenovirus-mediated high expression of BCL-6 in CV-1 cells induces apoptotic cell death accompanied by down-regulation of BCL-2 and BCL-X(L). Oncogene. 1999;18:487-94.
27. Albagli O, Lantoine D, Quief S, et al. Overexpressed BCL6 (LAZ3) oncoprotein triggers apoptosis, delays S phase progression and associates with replication foci. Oncogene. 1999;18:5063-75.
28. Kikuchi M, Miki T, Kumagai T, et al. Identification of negative regulatory regions within the first exon and intron of the BCL6 gene. Oncogene. 2000;19:4941-5.
29. Duechler M, Linke A, Cebula B, et al. In vitro cytotoxic effect of proteasome inhibitor bortezomib in combination with purine nucleoside analogues on chronic lymphocytic leukaemia cells. Eur J Haematol. 2005;74:407-17.